UCSF understands the importance of academic-industry partnerships for making advancements to improve health. In this vein, we continue to expand strategic partnerships with industry to support our mission of accelerating research to improve health.
Catalyst is helping to bridge the gap between UCSF's outstanding scientists and invaluable industry expertise.
Director, Catalyst Program
Our Catalyst Program supports the early development of therapeutics, diagnostics, devices, and digital health at UCSF and institutions. Catalyst aims to build innovative collaboration models that are mutually beneficial for UCSF researchers and industry partners. Partners collaborate through the Catalyst Awards and often extend their engagement with the broader UCSF community.
- Quest Diagnostics, the world's leading provider of diagnostic information services, to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes. Press
- MedImmune, the global biologics research and development arm of AstraZeneca, to benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios. The effort supports therapeutics including cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; neuroscience and infectious disease. Press
- Surpass, Inc, preclinical Contract Research Organization with expertise in development of medical devices, pharmaceuticals, and biologics. The partnership supports researchers via Surpass Innovation Awards. Press
- MilliporeSigma, a leading Life Science and Technology company. As part of the involvement in the Catalyst Award review panel, Sigma-Aldrich provides technical insight and market guidance to enable rapid translation into useful research tools and reagents. Press
- Sun Pharmaceuticals, a leading specialty generic pharmaceutical company.
- In addition, industry partners regularly sponsor Catalyst events and seminars that bring together academic researcher and members of the private sector.